[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse TCEB3B

Summary
SymbolTCEB3B
Nametranscription elongation factor B polypeptide 3B (elongin A2)
Aliases HsT832; TCEB3L; transcription elongation factor (SIII) elongin A2; elongin A2; ELOA2; elongin-A2; transcript ......
Chromosomal Location18q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF06881 RNA polymerase II transcription factor SIII (Elongin) subunit A
PF08711 TFIIS helical bundle-like domain
Function

SIII, also known as elongin, is a general transcription elongation factor that increases the RNA polymerase II transcription elongation past template-encoded arresting sites. Subunit A2 is transcriptionally active but its transcription activity is not enhanced by binding to the dimeric complex of the SIII regulatory subunits B and C (elongin BC complex).

> Gene Ontology
 
Biological Process GO:0006354 DNA-templated transcription, elongation
GO:0006368 transcription elongation from RNA polymerase II promoter
GO:0032784 regulation of DNA-templated transcription, elongation
Molecular Function -
Cellular Component GO:0008023 transcription elongation factor complex
GO:0070449 elongin complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1643685: Disease
R-HSA-112387: Elongation arrest and recovery
R-HSA-167152: Formation of HIV elongation complex in the absence of HIV Tat
R-HSA-167200: Formation of HIV-1 elongation complex containing HIV-1 Tat
R-HSA-112382: Formation of RNA Pol II elongation complex
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-162906: HIV Infection
R-HSA-162587: HIV Life Cycle
R-HSA-167169: HIV Transcription Elongation
R-HSA-167287: HIV elongation arrest and recovery
R-HSA-5663205: Infectious disease
R-HSA-162599: Late Phase of HIV Life Cycle
R-HSA-167290: Pausing and recovery of HIV elongation
R-HSA-167238: Pausing and recovery of Tat-mediated HIV elongation
R-HSA-674695: RNA Polymerase II Pre-transcription Events
R-HSA-73857: RNA Polymerase II Transcription
R-HSA-75955: RNA Polymerase II Transcription Elongation
R-HSA-6796648: TP53 Regulates Transcription of DNA Repair Genes
R-HSA-167243: Tat-mediated HIV elongation arrest and recovery
R-HSA-167246: Tat-mediated elongation of the HIV-1 transcript
R-HSA-167172: Transcription of the HIV genome
R-HSA-3700989: Transcriptional Regulation by TP53
Summary
SymbolTCEB3B
Nametranscription elongation factor B polypeptide 3B (elongin A2)
Aliases HsT832; TCEB3L; transcription elongation factor (SIII) elongin A2; elongin A2; ELOA2; elongin-A2; transcript ......
Chromosomal Location18q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TCEB3B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTCEB3B
Nametranscription elongation factor B polypeptide 3B (elongin A2)
Aliases HsT832; TCEB3L; transcription elongation factor (SIII) elongin A2; elongin A2; ELOA2; elongin-A2; transcript ......
Chromosomal Location18q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TCEB3B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTCEB3B
Nametranscription elongation factor B polypeptide 3B (elongin A2)
Aliases HsT832; TCEB3L; transcription elongation factor (SIII) elongin A2; elongin A2; ELOA2; elongin-A2; transcript ......
Chromosomal Location18q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TCEB3B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.010.0668
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.8660.243
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0750.968
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.3410.0266
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TCEB3B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277318.54.114.40.0315
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275918.55.113.40.102
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.529.4-19.90.207
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.516.7-4.21
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.736.4-28.70.142
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.97.40.51
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTCEB3B
Nametranscription elongation factor B polypeptide 3B (elongin A2)
Aliases HsT832; TCEB3L; transcription elongation factor (SIII) elongin A2; elongin A2; ELOA2; elongin-A2; transcript ......
Chromosomal Location18q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TCEB3B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTCEB3B
Nametranscription elongation factor B polypeptide 3B (elongin A2)
Aliases HsT832; TCEB3L; transcription elongation factor (SIII) elongin A2; elongin A2; ELOA2; elongin-A2; transcript ......
Chromosomal Location18q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TCEB3B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TCEB3B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTCEB3B
Nametranscription elongation factor B polypeptide 3B (elongin A2)
Aliases HsT832; TCEB3L; transcription elongation factor (SIII) elongin A2; elongin A2; ELOA2; elongin-A2; transcript ......
Chromosomal Location18q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TCEB3B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTCEB3B
Nametranscription elongation factor B polypeptide 3B (elongin A2)
Aliases HsT832; TCEB3L; transcription elongation factor (SIII) elongin A2; elongin A2; ELOA2; elongin-A2; transcript ......
Chromosomal Location18q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TCEB3B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTCEB3B
Nametranscription elongation factor B polypeptide 3B (elongin A2)
Aliases HsT832; TCEB3L; transcription elongation factor (SIII) elongin A2; elongin A2; ELOA2; elongin-A2; transcript ......
Chromosomal Location18q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TCEB3B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTCEB3B
Nametranscription elongation factor B polypeptide 3B (elongin A2)
Aliases HsT832; TCEB3L; transcription elongation factor (SIII) elongin A2; elongin A2; ELOA2; elongin-A2; transcript ......
Chromosomal Location18q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TCEB3B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.